Sleep Apnea Device Developer Signifier Closes $10M Series C Round
Signifier Medical Technologies, which markets the Snoozeal device for snoring and is developing a device for mild sleep apnea, has closed a circa $10M Series C funding round led by Alan Howard, VC investor and co-founder of Brevan Howard. The proceeds will allow Signifier to invest further in its solutions for patients with sleep-disordered breathing conditions.
The financing round also included participation from James Blair, a career healthcare venture capitalist and Partner/Co-founder of Domain Associates as an additional new investor in Signifier. Existing investors participating in the round included The Pritzker Organization and Signifier’s Chairman Kieran Gallahue, former CEO of both CareFusion and Resmed.
Howard says in a release, “I look for companies that are addressing extensive market opportunities, are rapidly growing, and have experienced leadership teams. I strongly believe Signifier is one of those companies, and I am pleased to support its transformational innovation to address sleep and breathing disorders and chronic care management.”
Joseph Gleberman, managing director of The Pritzker Organization, says in a release, “We are pleased to continue supporting Signifier’s breakthrough technology for treating both chronic snoring and obstructive sleep apnea.”
James Blair says in a release, “I am delighted to become an investor in Signifier, which is combining the tools of information technology with the knowledge of leading physicians to improve the daily lives of millions of people suffering from sleep-disordered breathing both conveniently and inexpensively.”
Signifier is continuing to build its operations and infrastructure in preparation for global commercialization of its eXciteOSA device for mild sleep apnea, while expanding commercialization of its Snoozeal device for primary snoring.
Akhil Tripathi, CEO and co-founder of Signifier Medical, says in a release, “I am delighted to have attracted such prominent and well-known investors in our latest financing round. Our noninvasive tongue muscle-neurostimulation devices are the first and only technologies being developed to solve the conditions of mild sleep apnea and snoring and make a real impact on the lives of millions of people worldwide.”
from Sleep Review https://www.sleepreviewmag.com/sleep-treatments/therapy-devices/emerging-technology/signifier-10m-seriesc-round/